Literature DB >> 18407351

Bone marrow fibroblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells.

J Edelmann1, L Klein-Hitpass, A Carpinteiro, A Führer, L Sellmann, S Stilgenbauer, U Dührsen, J Dürig.   

Abstract

Microarray-based gene expression profiling (GEP) was used to study how stroma modulates the survival of CLL cells in an in vitro coculture model employing the murine fibroblast cell line M2-10B4. CLL cells cultured in direct contact with the stromal layer (STR) showed a significantly better survival than cells cultured in transwell (TW) inserts above the M2-10B4 cells. STR as compared to TW conditions induced a significant up-regulation of PI3K/NF-kappaB pro-survival pathway genes and mediated a pro-angiogenetic switch in the CLL cells by up-regulation of vascular endothelial growth factor (VEGF) and osteopontin (OPN) and down-regulation of the anti-angiogenetic molecule thrombospondin-1 (TSP-1).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18407351     DOI: 10.1016/j.leukres.2008.03.003

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  25 in total

Review 1.  Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.

Authors:  Kumudha Balakrishnan; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2012-03-09       Impact factor: 6.206

Review 2.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

3.  Mechanism and Function of Angiogenin in Hematopoietic Malignancy.

Authors:  Kevin A Goncalves; Guo-Fu Hu
Journal:  Zhongguo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao       Date:  2015-12-23

4.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

Review 5.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

6.  Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.

Authors:  Deyan Yordanov Yosifov; Irina Idler; Nupur Bhattacharya; Michaela Reichenzeller; Viola Close; Daria Ezerina; Annika Scheffold; Billy Michael Chelliah Jebaraj; Sabrina Kugler; Johannes Bloehdorn; Jasmin Bahlo; Sandra Robrecht; Barbara Eichhorst; Kirsten Fischer; Anja Weigel; Hauke Busch; Peter Lichter; Hartmut Döhner; Tobias P Dick; Stephan Stilgenbauer; Daniel Mertens
Journal:  Leukemia       Date:  2019-07-12       Impact factor: 11.528

7.  Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Authors:  Sarah E M Herman; Amber L Gordon; Amy J Wagner; Nyla A Heerema; Weiqiang Zhao; Joseph M Flynn; Jeffrey Jones; Leslie Andritsos; Kamal D Puri; Brian J Lannutti; Neill A Giese; Xiaoli Zhang; Lai Wei; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2010-06-03       Impact factor: 22.113

8.  Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis.

Authors:  Wei Ding; Tait D Shanafelt; Connie E Lesnick; Charles Erlichman; Jose F Leis; Charla Secreto; Traci R Sassoon; Timothy G Call; Deborah A Bowen; Michael Conte; Shaji Kumar; Neil E Kay
Journal:  Br J Haematol       Date:  2013-09-20       Impact factor: 6.998

9.  Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia.

Authors:  Michal Reichert
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

10.  Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts.

Authors:  Paola Secchiero; Sonia Zorzet; Claudio Tripodo; Federica Corallini; Elisabetta Melloni; Lorenzo Caruso; Raffaella Bosco; Sabrina Ingrao; Barbara Zavan; Giorgio Zauli
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.